RxDoctor Payments Data

Gil Johnson, MD

Adult Medicine · Conway, ARNPI 1356563241

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 31 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 13 manufacturers reported payments, led by Novo Nordisk at 25.2% of the total.

$984in general payments, 2019–2025

Across 31 payments — averaging $31.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$248
  • Lilly USA, LLC$153
  • Pfizer$102
  • Boehringer Ingelheim$90
  • GSK$86
  • Phadia US Inc.$86
  • plus $219 from 7 others

What the payments were for

  • Food & beverage$984100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

Too few adult medicine providers in Arkansasto place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$134,729
Medicare patients
182
Services billed
1,701

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide49$59,949
EliquisApixaban67$45,065
TrulicityDulaglutide19$33,927
JanuviaSitagliptin Phosphate30$31,654
JardianceEmpagliflozin19$16,172
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog17$7,284
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog11$6,234
Incruse ElliptaUmeclidinium Bromide11$3,568
Lantus SolostarInsulin Glargine,hum.Rec.Anlog18$3,157
SynthroidLevothyroxine Sodium42$2,523
Ezetimibe-SimvastatinEzetimibe/Simvastatin16$2,409
Novolin 70-30Insulin Nph Hum/Reg Insulin Hm24$2,393
Febuxostat19$1,814
Irbesartan84$1,599
Atorvastatin Calcium241$1,470

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$248$59,94949 claims
PfizerEliquis$102$45,06567 claims
Lilly USA, LLCTrulicity$153$33,92719 claims
Boehringer IngelheimJardiance$90$16,17219 claims
GSKIncruse Ellipta$86$3,56811 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few adult medicine providers in Arkansason file to place this against a meaningful peer group, so we don't.

Other adult medicine in Conway

See the full list for Arkansas

Where these figures come from

Is this you, or does something look wrong? →